Vertex Pharmaceuticals Incorporated

What they do

Vertex develops and commercializes transformative medicines for serious diseases, focusing on specialty markets. Its approved products include CF therapies (TRIKAFTA, KAFTRIO, SYMDEKO, ORKAMBI, KALYDECO), CASGEVY for sickle cell disease and beta thalassemia, JOURNAVX for acute pain, and ALYFTREK (a next-generation CF therapy). The company invests heavily in R&D across multiple modalities, including small molecules, biologics, and cell therapies.

Revenue drivers

• Cystic fibrosis (CF) franchise — Core revenue driver, led by TRIKAFTA and ALYFTREK; strong patient demand and higher realized net prices in the U.S. drove growth in Q2 2026; CF continues to generate the majority of total revenue.
• CASGEVY (sickle cell disease and transfusion-dependent beta thalassemia) — Gene-edited cell therapy; revenue grew in Q2 2026 with increased infusions both in the U.S. and internationally; part of the non-CF product portfolio expected to contribute $500 million or more in 2026.
• JOURNAVX (acute pain) — Approved non-opioid NaV1.8 pain signal inhibitor; launched and contributing to revenue; commercial investment to support launch increased operating expenses in Q2 2026.

Recent performance

For Q2 2026, total revenue was $3.33 billion, up 12% year-over-year, with U.S. revenue up 11% to $2.06 billion and ex-U.S. up 14% to $1.28 billion. GAAP net income was $1.10 billion, or $4.31 per diluted share, compared to $1.03 billion ($3.99 per share) in Q2 2025. Cash, cash equivalents, and marketable securities totaled $13.6 billion at June 30, 2026, up from $12.3 billion at year-end 2025. Operating expenses increased as management invested in JOURNAVX launch and renal franchise build-out.

Strategy

Vertex's core strategy is to discover, develop, and commercialize innovative medicines by combining transformative advances in the understanding of human disease and the science of therapeutics, focusing on validated targets that address causal human biology, predictive lab assays and clinical biomarkers, rapid paths to registration and approval, and product candidates with transformative patient benefit. The company plans to serially innovate, following first-in-class therapies with potential best-in-class candidates, and invests in business development to access emerging technologies, products, and product candidates. Management is building a renal franchise led by povetacicept in IgA nephropathy and is diversifying into rare endocrine diseases through the pending acquisition of Crinetics Pharmaceuticals. They are also advancing programs in APOL1-mediated kidney disease, neuropathic pain, type 1 diabetes, and primary membranous nephropathy.

Risks

• Clinical and regulatory setbacks — Zimislecel dosing is temporarily postponed pending an internal manufacturing analysis, which could delay the type 1 diabetes program.
• Reliance on CF franchise — CF therapies drive the majority of revenue; any decline in CF drug performance or pricing pressure could materially impact results.
• Launch execution risk — JOURNAVX (acute pain) and CASGEVY (sickle cell/beta thalassemia) are newer products requiring successful commercial execution; slower-than-expected uptake could hurt guidance.
• Pending acquisition integration — The Crinetics acquisition is expected to close in Q3 2026 but is subject to customary conditions; integration risks and potential dilution could affect financials.

Outlook

Vertex raised full-year 2026 total revenue guidance to $13.1–13.2 billion from $12.95–13.1 billion, expecting continued CF growth and $500 million or more from non-CF products (CASGEVY and JOURNAVX). The guidance reflects a ~150 basis point benefit from foreign exchange, net of hedging, and an immaterial tariff impact. Management reiterated combined GAAP R&D, AIPR&D, and SG&A expense guidance of $6.3–6.45 billion (GAAP) and $5.65–5.75 billion (non-GAAP), and a non-GAAP effective tax rate of 19.5–20.5%. The guidance does not include the Crinetics acquisition; updated guidance will be provided after close.